KLOW Stack 80mg Research Guide

Compound Guide

KLOW Stack 80mg — GHK-Cu + BPC-157 + TB-500 + KPV

Multi-compound skin, gut & tissue-repair blend · Single lyophilised vial · SubQ · Faint blue tint is normal

Quick Start

ℹ️

One Vial, Four Compounds

The 80mg KLOW Stack is a single lyophilised vial containing GHK-Cu 50mg, BPC-157 10mg, TB-500 10mg, and KPV 10mg co-formulated together. You reconstitute and draw once — every draw delivers all four compounds in fixed proportion (62.5% / 12.5% / 12.5% / 12.5%). Reconstituted solution has a faint blue tint from the copper ion — this is normal.

What It Is

The KLOW Stack combines four research peptides with complementary repair and anti-inflammatory mechanisms in one vial: GHK-Cu (copper tripeptide — collagen and skin research), BPC-157 (pentadecapeptide — angiogenesis and localised healing), TB-500 (thymosin beta-4 fragment — systemic cell migration and repair), and KPV (α-MSH tripeptide fragment — anti-inflammatory signalling). Studied together for synergistic effects on skin, gut lining, connective tissue, and wound healing.

Research Route

SubQ injection is the studied route for the combined blend. Because all four compounds are in one vial, dosing is done by total draw volume rather than per-compound. A typical research draw of 10 units (U-100) delivers ~2.67mg of total blend — see the Dosing Protocol and Reconstitution tables below for the per-compound breakdown.

Regulatory Status

None of the four compounds are FDA-approved for injectable use. Topical GHK-Cu (as Copper Tripeptide-1) is a permitted cosmetic ingredient; the injectable forms are supplied for research purposes only. Not for human or veterinary therapeutic use.

Composition — 80mg Vial

Compound	Mass / Vial	Share of Blend	Primary Research Context
GHK-Cu	50 mg	62.5%	Collagen remodelling, skin photoaging, copper transport
BPC-157	10 mg	12.5%	Angiogenesis, tendon/gut/localised repair
TB-500 (TB-4 frag.)	10 mg	12.5%	Systemic cell migration, tissue & muscle repair
KPV	10 mg	12.5%	Anti-inflammatory signalling, gut & skin inflammation
Total	80 mg	100%	Single lyophilised, co-formulated vial

99% purity per compound. Third-party tested by Janoshik Analytical. Proportions are fixed in the powder — every reconstituted draw carries all four in the ratio above.

Dosing Protocol

Because the blend is fixed, protocols are defined by draw volume (units). The table shows what each daily draw delivers per compound, based on a 3 mL reconstitution (26.67 mg/mL total).

Draw (U-100)	Volume	Total Blend	GHK-Cu	BPC-157	TB-500	KPV
6 units	0.06 mL	1.60 mg	1.00 mg	0.20 mg	0.20 mg	0.20 mg
10 units	0.10 mL	2.67 mg	1.67 mg	0.33 mg	0.33 mg	0.33 mg
12 units	0.12 mL	3.20 mg	2.00 mg	0.40 mg	0.40 mg	0.40 mg
15 units	0.15 mL	4.00 mg	2.50 mg	0.50 mg	0.50 mg	0.50 mg

Common research protocol: 10 units once daily for 4–6 weeks, then re-evaluate. At 10 units/day an 80mg vial yields 30 doses (~30 days). This keeps the GHK-Cu component in its studied 1–2 mg/day range while delivering daily micro-amounts of BPC-157, TB-500 and KPV.

ℹ️

Loading vs Maintenance

TB-500 protocols in the literature often use a higher "loading" frequency (e.g. twice weekly at a larger dose) followed by maintenance. In a fixed blend this can't be isolated — daily low-dose administration is the practical compromise for a co-formulated vial. Adjust total daily units, not individual compounds.

Supplies & Reconstitution

Reconstitution Math — 80 mg Vial (3 mL BAC)

Draw (U-100)	Total Blend	Doses / Vial
6 units	1.60 mg	50
10 units	2.67 mg	30
12 units	3.20 mg	25
15 units	4.00 mg	20

Reconstitute the 80 mg vial with 3.0 mL bacteriostatic water (sold separately) → 26.67 mg/mL. U-100 syringe = 100 units per mL, so each unit delivers 0.267 mg of total blend. Swirl gently — do not shake. Refrigerate 2–8°C.

Reconstitution Steps

Warm the vial

Allow the lyophilised vial to reach room temperature (10–15 min from freezer).

Swab both stoppers

Wipe the tops of the peptide vial and the BAC water vial with fresh alcohol swabs. Allow to air-dry.

Draw 3.0 mL BAC water

Draw 3.0 mL bacteriostatic water — use a larger syringe for the full volume, or several insulin-syringe draws.

Inject along the wall

Run the BAC water slowly down the inside wall of the peptide vial. Do not jet directly onto the powder.

Swirl gently

Swirl slowly until fully dissolved. The solution will take on a faint blue tint from the copper — this is normal. Do not shake.

Refrigerate

Store at 2–8°C, upright, for up to 30 days. Protect from light. Discard if the colour turns yellow or if particles appear.

Mechanism of Action

GHK-Cu · Collagen & Copper

Activates TGF-β1 and collagen synthesis in fibroblasts while remodelling damaged collagen via MMP regulation. Chelates and delivers copper (Cu²⁺), a cofactor for lysyl oxidase and superoxide dismutase. Strongest human evidence is topical.

BPC-157 · Angiogenesis

Pentadecapeptide derived from a gastric protein. Studied for VEGFR2-driven angiogenesis and FAK-paxillin cell migration, with a research focus on tendon, ligament, and gut-lining repair.

TB-500 · Cell Migration

Thymosin beta-4 fragment. Sequesters G-actin and upregulates cell migration and differentiation, studied in systemic tissue repair, muscle, and inflammation models. Distributes widely rather than acting locally.

KPV · Anti-Inflammatory

C-terminal tripeptide (Lys-Pro-Val) of α-MSH. Studied for downregulating NF-κB and pro-inflammatory cytokine signalling in gut and skin models. Retains α-MSH's anti-inflammatory activity without pigmentary effects; researched in IBD, wound-healing and skin-inflammation contexts.

Proposed Synergy

The four are combined for overlapping but distinct pathways: GHK-Cu for dermal collagen, BPC-157 for localised angiogenesis, TB-500 for systemic migration, and KPV to temper the inflammatory response — studied together in skin, gut and connective-tissue research contexts.

Research Notes & Contraindications

⚠️

Copper Metabolism Disorders

The GHK-Cu component delivers bioavailable copper. Research protocols exclude subjects with Wilson's disease (impaired copper excretion), Menkes syndrome, or other known copper metabolism disorders. This is a clear contraindication for the blend.

⚠️

Limited Injectable Human Data

Human RCT evidence is limited to topical GHK-Cu. BPC-157, TB-500 and KPV injectable data are predominantly preclinical (animal/in-vitro). Extrapolating to a co-formulated injectable blend is not established and should be treated strictly as a research context.

Storage

State	Temperature	Duration	Notes
Lyophilised (powder)	−20°C (freezer)	Up to 24 months	Protect from light and moisture
Reconstituted (liquid)	2–8°C (refrigerator)	Up to 30 days	Faint blue colour is normal; discard if yellow or cloudy
Short-term (travel)	<25°C	Up to 72 hours	Avoid direct sunlight

⚠️

Disclaimer

This document is an educational research reference only. It is not medical advice, not a treatment plan, and not a recommendation to use GHK-Cu, BPC-157, TB-500, or KPV outside of a qualified research context. Injectable evidence for these compounds is limited; the GHK-Cu component is contraindicated where a copper metabolism disorder is present. By purchasing from LA LAB you confirm you are 18+ and that products are for research purposes only.